

October 7, 2002

AnGes MG, Inc.

Announcement regarding newspaper reports

Last weekend, some newspapers carried a report that France's national health agency decided to partially cancel genetic medication. The report says that similar therapy will be suspended in the United States. The therapy is intended for severe X-linked combined immunodeficiency. It has been confirmed that this therapy may have caused leukemia in some patients.

The genetic medication is a technology for introducing therapeutic genes into cells and involves the use of a genetic vector made from the leukemia virus found in mice. This technology is characterized by the therapeutic genes that are randomly injected in chromosomes. It has been pointed out that these therapeutic genes could be the cause of the onset of leukemia in this case.

Our company is proceeding with the development of HGF genetic medications for ischemic disease. Usually, we inject annular genes (plasmids) directly to introduce the therapeutic genes. The advantage of this method is that it is safe, and there is no possibility of the genes finding their way into the chromosomes.

For these reasons, the suspension of genetic medication in France and the United States has nothing to do with our company's HGF genetic medication. We will continue to develop our HGF genetic medication as planned.